This site is intended for US health care professionals only.
158 days to go: ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
*Demonstrated in 2 pivotal trials for adductor canal block and sciatic nerve block in the popliteal fossa.
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services.
This site is intended to provide medical and product information to health care professionals in the United States.
To report an adverse event, email drugsafety@pacira.com or call 1-855-793-9727.
For medical inquiries related to EXPAREL, submit a request to Medical Information or call 1-855-793-9727.
These are not all of the potential important safety considerations for EXPAREL; please see the full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Please refer to full Prescribing Information.
EXPAREL® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.
Important Safety Information
Increased reimbursement in the ambulatory surgery center and hospital outpatient department setting
Effective January 1, 2025, Medicare will provide separate ASP+6% reimbursement for proven non-opioid pain management, like EXPAREL, thanks to the NOPAIN Act.1-3
This will expand reimbursement beyond the ambulatory surgery center, where EXPAREL already has reimbursement via code C9290.
Keep me informed about the NOPAIN Act
ASP, average sales price; NOPAIN, Non-Opioids Prevent Addiction in the Nation.
References: 1. Congress.gov. One hundred seventeenth congress of the United States of America. Accessed June 12, 2024. https://www.congress.gov/117/bills/hr2617/BILLS-117hr2617enr.pdf 2. CMS.gov. Medicare part B drug average sales price. Accessed June 5, 2024. https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price 3. EXPAREL Prescribing Information. San Diego, CA; Pacira Pharmaceuticals, Inc., November 2023.
